Joel Greenblatt's REGN Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 80,271 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $61.96 M, representing 0.23% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 57,225 shares. Largest reduction occurred in Q4 2017, reducing 30,016 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -3,959 | Reduce 4.70% | 80,271 | $771.87 |
| Q3 2025 | +57,225 | Add 211.91% | 84,230 | $562.27 |
| Q2 2025 | -5,042 | Reduce 15.73% | 27,005 | $525.00 |
| Q1 2025 | +20,624 | Add 180.55% | 32,047 | $634.23 |
| Q4 2024 | +5,796 | Add 103.00% | 11,423 | $712.33 |
| Q3 2024 | -73 | Reduce 1.28% | 5,627 | $1051.24 |
| Q2 2024 | +2,345 | Add 69.90% | 5,700 | $1051.03 |
| Q1 2024 | +206 | Add 6.54% | 3,355 | $962.49 |
| Q4 2023 | -98 | Reduce 3.02% | 3,149 | $878.29 |
| Q3 2023 | -6,606 | Reduce 67.05% | 3,247 | $822.96 |
| Q2 2023 | +5,897 | Add 149.06% | 9,853 | $718.54 |
| Q1 2023 | -228 | Reduce 5.45% | 3,956 | $821.67 |
| Q4 2022 | -1,386 | Reduce 24.88% | 4,184 | $721.49 |
| Q3 2022 | -8,660 | Reduce 60.86% | 5,570 | $688.87 |
| Q2 2022 | -870 | Reduce 5.76% | 14,230 | $591.15 |
| Q1 2022 | -8,564 | Reduce 36.19% | 15,100 | $698.41 |
| Q4 2021 | +18,261 | Add 337.98% | 23,664 | $631.51 |
| Q3 2021 | +1,871 | Add 52.97% | 5,403 | $605.22 |
| Q2 2021 | +267 | Add 8.18% | 3,532 | $558.61 |
| Q1 2021 | -778 | Reduce 19.24% | 3,265 | $473.20 |
| Q4 2020 | -8,786 | Reduce 68.49% | 4,043 | $483.06 |
| Q3 2020 | +8,581 | Add 202.00% | 12,829 | $559.75 |
| Q2 2020 | -668 | Reduce 13.59% | 4,248 | $623.59 |
| Q1 2020 | +3,184 | Add 183.83% | 4,916 | $488.20 |
| Q4 2019 | -3,681 | Reduce 68.00% | 1,732 | $375.29 |
| Q3 2019 | -28,527 | Reduce 84.05% | 5,413 | $277.48 |
| Q2 2019 | +18,900 | Add 125.66% | 33,940 | $312.99 |
| Q1 2019 | +3,954 | Add 35.67% | 15,040 | $410.64 |
| Q4 2018 | -910 | Reduce 7.59% | 11,086 | $373.53 |
| Q3 2018 | -10,026 | Reduce 45.53% | 11,996 | $404.05 |
| Q2 2018 | +17,972 | Add 443.75% | 22,022 | $344.97 |
| Q1 2018 | -109 | Reduce 2.62% | 4,050 | $344.44 |
| Q4 2017 | -30,016 | Reduce 87.83% | 4,159 | $376.05 |
| Q3 2017 | +34,175 | New Buy | 34,175 | $447.11 |
| Q1 2017 | -12,096 | Sold Out | 0 | $0.00 |
| Q4 2016 | -12,649 | Reduce 51.12% | 12,096 | $367.06 |
| Q3 2016 | -5,406 | Reduce 17.93% | 24,745 | $402.02 |
| Q2 2016 | +27,626 | Add 1094.10% | 30,151 | $349.24 |
| Q1 2016 | -1,632 | Reduce 39.26% | 2,525 | $360.40 |
| Q4 2015 | +4,157 | New Buy | 4,157 | $542.94 |
| Q4 2014 | -1,410 | Sold Out | 0 | $0.00 |
| Q3 2014 | +529 | Add 60.05% | 1,410 | $360.28 |
| Q2 2014 | +881 | New Buy | 881 | $282.63 |
| Q4 2013 | -3,285 | Sold Out | 0 | $0.00 |
| Q3 2013 | +3,285 | New Buy | 3,285 | $312.94 |
Joel Greenblatt's Regeneron Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q3 2013, acquiring 3,285 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Regeneron Pharmaceuticals, Inc. (REGN) for 45 quarters since Q3 2013.
Joel Greenblatt's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q3 2025, adding 84,230 shares worth $47.36 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 80,271 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $61.96 M.
As of the Q4 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.23% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 84,230 shares, as reported at the end of Q3 2025.